SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Oct 3, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy
Cardiovascular events decline for patients using which antidiabetic medication?
Life threatening cardiovascular events can take place with uncontrolled type 2 diabetes, including death, heart failure, stroke, and myocardial infarction. Patients can also suffer from acute kidney disease. The purpose of this study is to compare the use of two antidiabetic medications, SGLT-2 inhibitor and GLP-1 receptor agonist, as it pertains to cardiovascular events. Previous studies, Dapagliflozin Effect on Cardiovascular Events (DECLARE) and Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) documented cardiovascular benefits for both medications. Another analysis performed on Italian outpatients with diabetes found benefits in glycemic control, HbA1c, blood pressure, and body weights were comparable. The authors stated that no clinical trials determine which drug is more effective in type 2 patients to protect them from cardiovascular events....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.